Stent Thrombosis
Novel stent for long coronary lesions linked with low rate of target lesion failure
A novel 48-mm stent for the treatment of diffuse de novo coronary artery lesions was found to be safe and effective at 1 year, with a high level of device deliverability, a speaker reported.
Cangrelor reduces ischemic events vs. clopidogrel early after PCI
Treatment with the IV P2Y12 inhibitor cangrelor reduced the number of early ischemic events after PCI, primarily MI and stent thrombosis, compared with oral clopidogrel, according to the results of the CHAMPION PHOENIX trial.
EVOLVE Short DAPT
DAPT for 3 months or 12 months after PCI with an everolimus-eluting stent (Synergy, Boston Scientific).
Bivalirudin may reduce risk for 30-day mortality after PCI in STEMI
Compared with heparin, bivalirudin reduced the risk for 30-day mortality, serious bleeding and net adverse clinical events in patients with STEMI undergoing PCI despite increased rates of stent thrombosis and MI, researchers found.
Self-expanding stent beneficial in venous outflow obstruction
Among patients with venous outflow obstruction, a self-expanding venous stent system was safe and effective, researchers reported at the virtual Charing Cross Symposium.
TAILOR PCI
Determine whether genetic testing identifies an antiplatelet therapy for patients undergoing PCI who do not tolerate clopidogrel well.
Ticagrelor monotherapy reduces bleeding risk after PCI regardless of DES platform
Among patients who underwent PCI with a drug-eluting stent and were prescribed dual antiplatelet therapy for 3 months, subsequent ticagrelor monotherapy reduced bleeding risk compared with continued DAPT regardless of DES type, according to results from the TWILIGHT-SYNERGY study.
Ticagrelor monotherapy beneficial after PCI with ultrathin SES
Among patients with ACS who underwent PCI with an ultrathin biodegradable polymer sirolimus-eluting stent, ticagrelor monotherapy after 3 months was superior at preventing net adverse clinical events compared with prolonged dual antiplatelet therapy with ticagrelor and aspirin, according to the results of the TICO trial.
Ticagrelor monotherapy beneficial in complex PCI, diabetes: New TWILIGHT data
In new findings from the TWILIGHT trial of patients who underwent PCI, switching from dual antiplatelet therapy to ticagrelor monotherapy after 3 months benefited patients who had complex PCI and patients with diabetes.
In PCI with dual-therapy stent, no sex differences at 1 year
At 1 year, women experienced similar target lesion failure and ischemic outcomes compared with men after PCI with a dual-therapy stent, according to research published in Catheterization and Cardiovascular Interventions.